CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor

LONDON – 18 August 2026 — CHARM Therapeutics (“CHARM”, “The Company”), a biotechnology company addressing resistance in acute myeloid leukemia (AML) with a best-in-class menin inhibitor, announces the formation of its Clinical Advisory Board to support the advancement of CHM-029 into clinical...